Advertisement

Medical Oncology

, Volume 13, Issue 3, pp 177–184 | Cite as

Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters

  • L. S. Hofstra
  • E. G. E. De Vries
  • C. A. Uyl-De Groot
  • E. Vellenga
Review
  • 25 Downloads

Abstract

Recombinant human growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), have been only available for a few years. Since their introduction they have affected the management of drug-induced neutropenia, the use of dose intensive chemotherapy regimens and in the setting of autologous stem cell transplantation. This review addresses the clinical role of GM-CSF, using the data available, in neutrophil recovery in relation to various health care parameters.

Keywords

GM-CSF neutrophil recovery health care 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wong, G.G., Witek, J.S. and Temple, P.A. (1985) Human GM-CSF: molecular cloning of the complementary DNA and puring of the natural and recombinant proteins.Science 228, 810–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Sieff, CA., Niemeyer, CM., Mentzer, S.J.et al. (1988) Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells.Blood 72, 1316–23.PubMedGoogle Scholar
  3. 3.
    Vellenga, E., Rambaldi, A., Ernst, T.et al. (1988) Independent regulation of M-CSF and G-CSF gene expression in human monocytes.Blood 71, 1529–32.PubMedGoogle Scholar
  4. 4.
    Yang, Y.C., Tsai, S., Wong, G.G.et al. (1988) Interleukin-1 regulation of haematopoietic growth factor production by human stromal hbroblasts.J. Cell. Physiol. 134, 292–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Bagby Jr, G.C., Dinarello, C.A., Wallance, P.et al. (1986) Interleukin-1 stimulates granulocyte macrophage colony stimulating activity release by vascular endothelial cells.J. Clin. Invest 78, 1316–1623.PubMedCrossRefGoogle Scholar
  6. 6.
    Clarck, S.C. and Kamen, R. (1989) The human haematopoietic colony-stimulating factors.Science 236, 1229–37.CrossRefGoogle Scholar
  7. 7.
    Metcalf, D. (1985) The granulocyte-macrophage colony stimulating factors.Science 229, 16–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Sieff, C.A., Emerson, S.G., Donahue, R.E.et al. (1985) Human recombinant granulocyte-macrophage colony stimulating factor: a multilineage hematopoietin.Science 230, 1171–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Groopman, J., Mitsuyasu, R., deLeo, M.et al. (1987) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.N. Engl. J. Med. 317, 593–8.PubMedGoogle Scholar
  10. 10.
    Vadhan-Ray, S., Keating, M., Lemaistre, A.et al. (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.N. Engl. J. Med. 317, 1545–52.Google Scholar
  11. 11.
    Antman, K., Grifhn, J., Elias, A.et al. (1988) Effects of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy induced myelosuppression.N. Engl. J. Med. 319, 593–8.PubMedGoogle Scholar
  12. 12.
    Fleischmann, J., Golde, D.W., Weisbart, R.H.et al. (1986) Granulocyte-macrophage colony stimulating factor enhances phagocytosis of bacteria by human neutrophils.Blood 68, 708–11.PubMedGoogle Scholar
  13. 13.
    Wang, J.M., Colella, S., Alavena, P.et al. (1987) Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor.Immunology 60, 439–44.PubMedGoogle Scholar
  14. 14.
    Kaplan, S.S., Basford, R.E., Wing, E. J.et al. (1989) The effect of human granulocyte-macrophage colony-stimulating factor on neutrophil activation in patients with refractory carcinoma.Blood 73, 636–38.PubMedGoogle Scholar
  15. 15.
    Vadas, M.A., Nicola, N.A. and Metcalf, D. (1983) Activation of antibody dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony stimulating factors.J. Immunol. 130, 795–9.PubMedGoogle Scholar
  16. 16.
    Wing, E.J., Magee, D.M., Whiteside, T.L.et al. (1989) Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor and interferon in cancer patients.Blood 73, 643–6.PubMedGoogle Scholar
  17. 17.
    Cannistra, S.A., Vellenga, E., Groshek, P.et al. (1988) Human granulocyte-monocyte colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumour necrosis factor-dependent mechanism.Blood 71, 672–6.PubMedGoogle Scholar
  18. 18.
    Hazenberg, B.P.C., van Leeuwen, M.A., van Rijswijk, M.H.et al. (1989) Correction of granulocytopenia in Felty’s syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis.Blood 74, 2769–70.PubMedGoogle Scholar
  19. 19.
    de Vries, E.G.E., Willemse, P.H.B., Biesma, B.et al. (1991) Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy.Lancet 338, 517–8.PubMedGoogle Scholar
  20. 20.
    de Vries, E.G.E., Biesma, B., Willemse, P.H.B.et al. (1991) A double-blind placebo controlled study with macrophage colony stimulating factor during chemotherapy for ovarian carcinoma.Cancer Res. 51, 116–22.PubMedGoogle Scholar
  21. 21.
    Cantrell, M.A., Anderson, D., Cerretti, D.P.et al. (1985) Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor.Proc. Natl. Acad. Sci. USA 82, 6250–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Burgess, A.W., Begley, C.G., Johson, G.R.et al. (1987) Purification and properties of bacterially synthesized human granulocyte macrophage colony-stimulating factor.Blood 69, 43–51.PubMedGoogle Scholar
  23. 23.
    Donahue, R.E., Wang, E.A., Stone, D.K.et al. (1986) Stimulation of haemopoiesis in primates by continuous infusion of recombinant human GM-CSF.Nature 321, 872–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Mayer, P., Lam, C, Obenaus, H.et al. (1987) Recombinant human GM-CSF induces leucocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates.Blood 70, 206–13.PubMedGoogle Scholar
  25. 25.
    Nienhuis, A.W., Donahue, R.E., Karlsson, S.et al. (1987) Recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model.J. Clin. Invest. 80, 573–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Monroy, R.L., Skelly, R.R., MacVittie, T.J.et al. (1987) The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow.Blood 70, 1696–9.PubMedGoogle Scholar
  27. 27.
    Gerhartz, H.H., Engelhaed, M., Meuser, P.et al. (1993) Randomized double blind placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to induction treatment of high-grade malignant non-Hodgkin lymphomas.Blood 82, 2329–39.PubMedGoogle Scholar
  28. 28.
    Rowe, J.M., Andersen, J.W., Mazza, J.J.et al. (1995) A randomized placebo controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (> 55–70 years of age) with acute myelogenous leukaemia: A study of the Eastern Cooperative Oncology Group.Blood 86, 457–62.PubMedGoogle Scholar
  29. 29.
    Löwenberg, B., Uyl-de Groot, C, Suciu, S. et al. A randomized phase III study on the value of GM-CSF administration as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia. Submitted.Google Scholar
  30. 30.
    Stone, R., Berg, D., George, S.et al. (1995) Granulocyte- macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia.N. Engl. J. Med. 332, 1671–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Yau, J.C., Neidhart, J.A., Triozzi, P.et al. (1996) Randomized placebo controlled trial of granulocyte-macrophage colony-stimulating-factor support for dose intensive cyclophosphamide, etoposide and cisplatin.Am. J. Hematol. 51, 289–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Bunn, P.A., Crowley, J., Kelly, K.et al. (1995) Chemora- diotherapy with or without granulocyte-macrophage colony-stimulating factor m the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.J. Clin. Oncol. 13, 1632–41.PubMedGoogle Scholar
  33. 33.
    Bodey, G.P., Anaissie, E., Gutterman, J.et al. (1994) Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.Eur. J. Clin. Microbiol. Infect. Dis. 13, 18–22.CrossRefGoogle Scholar
  34. 34.
    O’Shaughnessy, J., Venzon, D., Gossard, M.et al. (1995) A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in patients with advanced breast cancer treated with FLAC chemotherapy.Blood 86, 2913–21.PubMedGoogle Scholar
  35. 35.
    O’Shaugnessy, J., Tolcher, A., Riseberg, D.et al. (1996) Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin and cvclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.Blood 15, 2205–11.Google Scholar
  36. 36.
    Riikonen, P., Saarinen, U.M., Makipernaa,et al. (1994) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with antibiotics in the treatment of febrile neutropenia: a double blind placebo controlled study in children.Pediatr. Inf. Dis. J. 13, 197- 200.CrossRefGoogle Scholar
  37. 37.
    Mayordomo, J.I., Rivera, F., Diaz-Puente, M.T.et al. (1995) Improving treatment of chemotherapy induced neutropenic fever by administration of colony stimulating factors.J. Natl. Cancer Inst. 87, 803–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Maher, D.W., Lieschke, G.J., Green, M.et al. (1994) Filgrastim in patients with chemotherapy induced febrile neutropenia. A double blind placebo controlled trial.Ann. Intern. Med. 121, 492–501.PubMedGoogle Scholar
  39. 39.
    Vellenga, E., Uyl-de Groot, C., de Wit, R.et al. (1996) Randomized placebo controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.J. Clin. Oncol. 14, 619–27.PubMedGoogle Scholar
  40. 40.
    Uyl-de Groot, C.A., Vellenga, E. and Rutten, F. (1996) An economic model to assess the savings from a clinical application of haemopoietic growth factors (HGF).Eur. J. Cancer 32A, 57–62.CrossRefGoogle Scholar
  41. 41.
    Malik, I., Khan, W., Karim, M.et al. (1995) Feasibility of outpatient management of fever in cancer patients with low risk neutropenia: results of a prospective randomized trial.Am. J. Med. 98, 224–31.PubMedCrossRefGoogle Scholar
  42. 42.
    Rubenstein, E., Rolston, K., Benjamin, R.et al. (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.Cancer 71, 3640–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Bash, R., Katz, J., Cash, J.et al. (1994) Safety and cost- effectiveness of early hospital discharge of lower risk children with children with cancer admitted for fever and neutropenia.Cancer 74, 189–96.PubMedCrossRefGoogle Scholar
  44. 44.
    Freifeld, A. and Pizzo, P. (1995) Colony stimulating factors and neutropenia: Intersection of data and clinical relevance.J. Natl. Cane. Inst 87, 781–2.CrossRefGoogle Scholar
  45. 45.
    Nemunaitis, J., Rabinowe, S.N., Singer, J.W.et al. (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.N, Engl. J. Med. 324, 1773–8.CrossRefGoogle Scholar
  46. 46.
    Gorin, N.C., Coiffer, B., Hayat, M.et al. (1992) Recombinant human granulocyte-macrophage colony-stimulating factor after high dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin’s lymphoma: A double-blind placebo-controlled trial.Blood 80, 1149–57.PubMedGoogle Scholar
  47. 47.
    Gulati, S.C. and Bennett, C.L. (1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct therapy in relapsed Hodgkin’s disease.Ann. Intern. Med. 116, 177–82.PubMedGoogle Scholar
  48. 48.
    Link, H., Boogaerts, M.A., Carella, A.M.et al. (1992) A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukaemia or malignant lymphoma.Blood 80, 2188–95.PubMedGoogle Scholar
  49. 49.
    Rabinowe, S.N., Neuberg, D., Bierman, P.J.et al. (1993) Long-term follow up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.Blood 81, 1903–8.PubMedGoogle Scholar
  50. 50.
    Brandt, S.J., Peters, W.P., Atwater, S.K.et al. (1988) Effect of recombinant human granulocyte-macrophage colony- stimulating factor on haematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation.N. Engl. J. Med. 318, 869–76.PubMedGoogle Scholar
  51. 51.
    Sheridan, W.P., Morstyn, G., Wolf, M.et al. (1989) Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.Lancet ii, 891–5.CrossRefGoogle Scholar
  52. 52.
    Taylor, K.M., Jagannath, S., Spitzer, G.et al. (1989) Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation.J. Clin. Oncol. 7, 1791–9.PubMedGoogle Scholar
  53. 53.
    Gisselbrecht, C, Prentice, H.G., Bacigalupo, A.et al. 1990 Placebo-controlled phase III trial of lenograstim in bone- marrow transplantation.Lancet 343, 696–700.CrossRefGoogle Scholar
  54. 54.
    Update of recommendations for the use of hemopoietic colony-stimulating factors: Evidence based clinical practice guidelines.J. Clin. Oncol. 14, 1957–60.Google Scholar
  55. 55.
    Gianni, A.M., Siena, S., Bregni, M.et al. 1998 Granulocytemacrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.Lancet ii, 580–5.Google Scholar
  56. 56.
    Kritz, A., Crown, J.P., Motzer, R.J.et al. (1993) Beneficial impact of peripheral blood progenitor cells in patients with metastaric breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.Cancer 71, 2515–21.PubMedCrossRefGoogle Scholar
  57. 57.
    Elias, A.D., Anderson, K.C., Hunt, M.et al. (1992) Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for haematologic support after high-dose intensification for breast cancer.Blood 79, 3036–44.PubMedGoogle Scholar
  58. 58.
    Peters, W.P., Rosner, G., Ross, M.et al. (1993) Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.Blood 8 1, 1709–19.Google Scholar
  59. 59.
    Rowlings, P.A., Brayly, J.L., Rawling, CM.et al. (1994) A comparison of peripheral blood stem cell mobilization after chemotherapy with cyclophosphamide as a single agent in doses of 4 g m-2 or 7 g m-2 in patients with advanced cancer.Aust. N.Z. J. Med. 22, 660–4.Google Scholar
  60. 60.
    Craig, J.I.O., Anthony, R.S., Thomson, E.B. et al. (1993) Successful mobilisation of peripheral blood stem cells using 2 different doses of cyclophosphamide with G-CSF in patients with lymphoma and breast cancer. Abstract book 3rd international symposium on peripheral blood stem cell autografts Bordeaux (France), (abstr 6).Google Scholar
  61. 61.
    Spitzer, G., Adkins, D.R., Spencer, V.etal. (1994) Randomized study of growth factors post-peripheral-blood stemcell transplant: Neutrophil recovery is improved with modest clinical benefit.J. Clin. Oncol. 12, 661–70.PubMedGoogle Scholar
  62. 62.
    Bensinger, W., Appelbaum, F., Rowley, S.et al. (1995) Factors that influence collection and engraftment of autologous peripheral blood stem cells.J. Clin. Oncol. 13, 2547–55.PubMedGoogle Scholar
  63. 63.
    Schmitz, N., Linch, D.C., Dreger, P.et al. (1996) Filgrastim- mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.Lancet 3, 47353–7.Google Scholar
  64. 64.
    Bolwell, B.J., Fishleder, A., Andresen, S.W.et al. (1993) G- CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.Bone Marrow Transpl. 12, 609–14.Google Scholar
  65. 65.
    De Graaf, H., Mulder, N.H., Willemse, P.H.B.et al. (1995) Additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.Anticancer Res. 15, 2851–6.PubMedGoogle Scholar
  66. 66.
    Brugger, W., Frisch, J.,. Schulz, G.et al. (1992) Sequential administration of interleukin-3 and granulocyte-macro- phage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.J. Clin. Oncol. 10, 1452–9.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1996

Authors and Affiliations

  • L. S. Hofstra
    • 1
  • E. G. E. De Vries
    • 1
  • C. A. Uyl-De Groot
    • 3
  • E. Vellenga
    • 2
  1. 1.Departments of OncologyThe Netherlands
  2. 2.Department of HematologyUniversity Hospital GroningenGroningenThe Netherlands
  3. 3.Institute for Medical Technology AssessmentErasmus UniversityRotterdamThe Netherlands

Personalised recommendations